$LGVN
Longeveron Inc. Stock $lgvn

$lgvn Overview Financials Valuation SEC Filings Company Website

2022 Q2 Form 10-Q Financial Statement

#000121390022047372 Filed on August 12, 2022

Income Statement

Concept	2022 Q2	2022 Q1	2021 Q4
Revenue	$466.0K	$370.0K	$209.0K
YoY Change	-4.7%	-2.63%	-82.29%
Cost Of Revenue	$306.0K	$70.00K	$140.0K
YoY Change	8.9%	-69.57%	-78.46%
Gross Profit	$160.0K	$300.0K	$69.00K
YoY Change	-23.08%	100.0%	-86.98%
Gross Profit Margin	34.33%	81.08%	33.01%
Selling, General & Admin	$2.661M	$2.267M	$2.368M
YoY Change	-19.61%	0.31%	211.58%
% of Gross Profit	1663.13%	755.67%	3431.88%
Research & Development	$1.720M	$1.427M	$1.733M
YoY Change	-12.24%	5.7%	50.7%
% of Gross Profit	1075.0%	475.67%	2511.59%
Depreciation & Amortization	$100.0K	$188.0K	$232.0K
YoY Change	0.0%	-6.0%	16.0%
% of Gross Profit	62.5%	62.67%	336.23%
Operating Expenses	$4.381M	$3.694M	$4.101M
YoY Change	-16.87%	2.61%	114.71%
Operating Profit	-$4.221M	-$3.394M	-$4.032M
YoY Change	-16.61%	-1.62%	192.17%
Interest Expense		-$100.0K	-$1.000K
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$1.403M	-$16.00K	-$36.00K
YoY Change	-2798.08%	-132.0%	-220.0%
Pretax Income	-$5.624M	-$3.510M	-$4.069M
YoY Change	12.26%	12.86%	199.19%
Income Tax
% Of Pretax Income
Net Earnings	-$5.624M	-$3.510M	-$4.069M
YoY Change	12.26%	12.86%	199.19%
Net Earnings / Revenue	-1206.87%	-948.65%	-1946.89%
Basic Earnings Per Share	-$0.27	-$0.17
Diluted Earnings Per Share	-$0.27	-$167.9K	-$203.1K
COMMON SHARES
Basic Shares Outstanding	20.94M shares	20.91M shares
Diluted Shares Outstanding	20.94M shares	20.91M shares

Balance Sheet

Concept	2022 Q2	2022 Q1	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$27.06M	$30.58M	$35.04M
YoY Change	26.52%	25.02%	4173.54%
Cash & Equivalents	$20.22M	$22.13M	$25.66M
Short-Term Investments	$6.837M	$8.449M	$9.385M
Other Short-Term Assets	$1.041M	$1.190M	$282.0K
YoY Change	75.55%	41.67%	-53.77%
Inventory
Prepaid Expenses
Receivables	$136.0K	$96.00K	$55.00K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$28.24M	$31.87M	$35.38M
YoY Change	27.71%	25.96%	1812.43%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.835M	$4.711M	$3.062M
YoY Change	-45.26%	-13.24%	-46.0%
Goodwill
YoY Change
Intangibles	$2.358M		$2.334M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$219.0K	$234.0K	$177.0K
YoY Change	23.73%	30.0%	-1.67%
Total Long-Term Assets	$7.087M	$7.306M	$7.386M
YoY Change	-8.51%	2.47%	-0.05%
TOTAL ASSETS
Total Short-Term Assets	$28.24M	$31.87M	$35.38M
Total Long-Term Assets	$7.087M	$7.306M	$7.386M
Total Assets	$35.33M	$39.17M	$42.77M
YoY Change	18.31%	20.79%	362.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$327.0K	$561.0K	$645.0K
YoY Change	119.46%	-37.67%	-59.43%
Accrued Expenses	$823.0K	$1.334M	$1.327M
YoY Change	-54.3%	-9.86%	-35.27%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Long-Term Debt Due			$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$3.618M	$2.400M	$2.708M
YoY Change	65.58%	-13.67%	-29.3%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Other Long-Term Liabilities	$2.326M	$2.467M	$2.605M
YoY Change	-19.15%	-18.04%	-17.04%
Total Long-Term Liabilities	$2.326M	$2.467M	$2.605M
YoY Change	-23.03%	-21.93%	-24.49%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.618M	$2.400M	$2.708M
Total Long-Term Liabilities	$2.326M	$2.467M	$2.605M
Total Liabilities	$5.944M	$4.867M	$5.313M
YoY Change	14.15%	-18.06%	-27.02%
SHAREHOLDERS EQUITY
Retained Earnings	-$53.07M		-$43.94M
YoY Change
Common Stock	$6.000K		$5.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$100.0K		$100.0K
YoY Change
Treasury Stock Shares
Shareholders Equity	$29.38M	$34.31M	$37.45M
YoY Change
Total Liabilities & Shareholders Equity	$35.33M	$39.17M	$42.77M
YoY Change	18.31%	20.79%	362.84%

Cashflow Statement

Concept	2022 Q2	2022 Q1	2021 Q4
OPERATING ACTIVITIES
Net Income	-$5.624M	-$3.510M	-$4.069M
YoY Change	12.26%	12.86%	199.19%
Depreciation, Depletion And Amortization	$100.0K	$188.0K	$232.0K
YoY Change	0.0%	-6.0%	16.0%
Cash From Operating Activities	-$3.275M	-$4.152M	-$1.281M
YoY Change	10.87%	37.03%	156.2%
INVESTING ACTIVITIES
Capital Expenditures	-$97.00K	-$118.0K	-$1.153M
YoY Change	-21.77%		2782.5%
Acquisitions
YoY Change
Other Investing Activities	$1.612M	$885.0K	-$162.0K
YoY Change	-135.56%
Cash From Investing Activities	$1.515M	$767.0K	-$1.315M
YoY Change	-132.53%		3187.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-148.0K	-141.0K	18.52M
YoY Change	572.73%	-100.53%	-61820.0%
NET CHANGE
Cash From Operating Activities	-3.275M	-4.152M	-1.281M
Cash From Investing Activities	1.515M	767.0K	-1.315M
Cash From Financing Activities	-148.0K	-141.0K	18.52M
Net Change In Cash	-1.908M	-3.526M	15.92M
YoY Change	-75.0%	-114.91%	-2892.98%
FREE CASH FLOW
Cash From Operating Activities	-$3.275M	-$4.152M	-$1.281M
Capital Expenditures	-$97.00K	-$118.0K	-$1.153M
Free Cash Flow	-$3.178M	-$4.034M	-$128.0K
YoY Change	12.3%	33.14%	-72.17%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40060
	dei	Entity Registrant Name EntityRegistrantName	Longeveron Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-2174146
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1951 NW 7th Avenue
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 520
	dei	Entity Address City Or Town EntityAddressCityOrTown	Miami
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2708000	usd
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33136
	dei	City Area Code CityAreaCode	(305)
	dei	Local Phone Number LocalPhoneNumber	909-0840
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	LGVN
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20224000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25658000	usd
CY2022Q2	us-gaap	Other Short Term Investments OtherShortTermInvestments	7081000	usd
CY2021Q4	us-gaap	Other Short Term Investments OtherShortTermInvestments	9471000	usd
CY2022Q2	us-gaap	Deferred Offering Costs DeferredOfferingCosts	6837000	usd
CY2021Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	9385000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1041000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	282000	usd
CY2022Q2	us-gaap	Grants Receivable Current GrantsReceivableCurrent	136000	usd
CY2021Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	55000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	28238000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	35380000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2835000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3062000	usd
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2358000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2334000	usd
CY2022Q2	lgvn	Rightofuse Rou Asset RightofuseROUAsset	1675000	usd
CY2021Q4	lgvn	Rightofuse Rou Asset RightofuseROUAsset	1813000	usd
CY2022Q2	us-gaap	Other Assets OtherAssets	219000	usd
CY2021Q4	us-gaap	Other Assets OtherAssets	177000	usd
CY2022Q2	us-gaap	Assets Assets	35325000	usd
CY2021Q4	us-gaap	Assets Assets	42766000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	327000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	645000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	823000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1327000	usd
CY2022Q2	us-gaap	Loans Payable Current LoansPayableCurrent	550000	usd
CY2021Q4	us-gaap	Loans Payable Current LoansPayableCurrent	537000	usd
CY2022Q2	us-gaap	Litigation Reserve Current LitigationReserveCurrent	1398000	usd
CY2022Q2	us-gaap	Deferred Revenue DeferredRevenue	520000	usd
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	199000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3618000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	52762	shares
CY2022Q2	lgvn	Lease Liability LeaseLiability	2326000	usd
CY2021Q4	lgvn	Lease Liability LeaseLiability	2605000	usd
CY2022Q2	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	2326000	usd
CY2021Q4	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	2605000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	5944000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	5313000	usd
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	5000	usd
CY2022Q2	lgvn	Common Stock Value One CommonStockValueOne	15000	usd
CY2021Q4	lgvn	Common Stock Value One CommonStockValueOne	16000	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	82532000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	81470000	usd
CY2022Q2	us-gaap	Treasury Stock Value TreasuryStockValue	100000	usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	100000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-53072000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-43938000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	29381000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	37453000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35325000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	42766000	usd
CY2022Q2	lgvn	Clinical Trial Income ClinicalTrialIncome	340000	usd
CY2021Q2	lgvn	Clinical Trial Income ClinicalTrialIncome	214000	usd
	lgvn	Clinical Trial Income ClinicalTrialIncome	650000	usd
	lgvn	Clinical Trial Income ClinicalTrialIncome	379000	usd
CY2022Q2	lgvn	Grant Income GrantIncome	126000	usd
CY2021Q2	lgvn	Grant Income GrantIncome	275000	usd
	lgvn	Grant Income GrantIncome	186000	usd
	lgvn	Grant Income GrantIncome	486000	usd
CY2022Q2	us-gaap	Revenues Revenues	466000	usd
CY2021Q2	us-gaap	Revenues Revenues	489000	usd
	us-gaap	Revenues Revenues	836000	usd
	us-gaap	Revenues Revenues	865000	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	306000	usd
CY2021Q2	us-gaap	Cost Of Revenue CostOfRevenue	281000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	376000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	508000	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	160000	usd
CY2021Q2	us-gaap	Gross Profit GrossProfit	208000	usd
	us-gaap	Gross Profit GrossProfit	460000	usd
	us-gaap	Gross Profit GrossProfit	357000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2427000	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3257000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4407000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4963000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1720000	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1960000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3147000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3310000	usd
CY2022Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	234000	usd
CY2021Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	53000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	521000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	605000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	4381000	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	5270000	usd
	us-gaap	Operating Expenses OperatingExpenses	8075000	usd
	us-gaap	Operating Expenses OperatingExpenses	8878000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4221000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5062000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7615000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8521000	usd
CY2022Q2	lgvn	Nonoperating Lawsuit Expense NonoperatingLawsuitExpense	1398000	usd
	lgvn	Nonoperating Lawsuit Expense NonoperatingLawsuitExpense	1398000	usd
	lgvn	Forgiveness Of Paycheck Protection Program Loan ForgivenessOfPaycheckProtectionProgramLoan	300000	usd
CY2021Q2	us-gaap	Interest Expense InterestExpense	2000	usd
	us-gaap	Interest Expense InterestExpense	2000	usd
CY2022Q2	us-gaap	Other Income OtherIncome	-5000	usd
CY2021Q2	us-gaap	Other Income OtherIncome	54000	usd
	us-gaap	Other Income OtherIncome	-121000	usd
	us-gaap	Other Income OtherIncome	100000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1403000	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	52000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1519000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	400000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-5624000	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-5010000	usd
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-9134000	usd
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-8121000	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20943897	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19005007	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20927640	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18252219	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	37453000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-294000	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	1356000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9134000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	29381000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1957	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2969000	usd
	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	26134000	usd
	lgvn	Class A Common Stock Issued For Consulting ClassACommonStockIssuedForConsulting	1197000	usd
	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	3483000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8121000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	24650000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	34306000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-166000	usd
CY2022Q2	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	865000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-5624000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	29381000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	26495000	usd
CY2021Q2	lgvn	Class A Common Stock Issued For Consulting ClassACommonStockIssuedForConsulting	946000	usd
CY2021Q2	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	2219000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-5010000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	24650000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9134000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8121000	usd
	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	417000	usd
	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	446000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	300000	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-123000	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	22000	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	170000	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	264000	usd
	lgvn	Equitybased Compensations EquitybasedCompensations	1186000	usd
	lgvn	Equitybased Compensations EquitybasedCompensations	3483000	usd
	us-gaap	Other Nonrecurring Expense OtherNonrecurringExpense	1398000	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	82000	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-291000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	759000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	541000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	42000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-241000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1389000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	321000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	220000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-504000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-188000	usd
	lgvn	Increase Decrease Lease Liability IncreaseDecreaseLeaseLiability	280000	usd
	lgvn	Increase Decrease Lease Liability IncreaseDecreaseLeaseLiability	127000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7427000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5984000	usd
	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	-2497000	usd
	us-gaap	Payments For Proceeds From Short Term Investments PaymentsForProceedsFromShortTermInvestments	4533000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	125000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	90000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	124000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2282000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4657000	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	26696000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	289000	usd
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	38000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-289000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	26658000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-5434000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	16017000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25658000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	816000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20224000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16833000	usd
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	2057000	usd
	lgvn	Vesting Of Rs Us Into Class A Common Stock VestingOfRSUsIntoClassACommonStock	-1017000	usd
CY2021Q4	us-gaap	Partners Capital Account Units Sold In Private Placement PartnersCapitalAccountUnitsSoldInPrivatePlacement	1169288	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P5Y
	lgvn	Recurring Loss RecurringLoss	9100000	usd
	lgvn	Recurring Loss RecurringLoss	8100000	usd
CY2022Q2	lgvn	Accmulated Deficit AccmulatedDeficit	53100000	usd
CY2022Q2	us-gaap	Cash Cash	20200000	usd
CY2022Q2	lgvn	Short Term Investments Amount ShortTermInvestmentsAmount	6800000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Use of estimates:</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">The presentation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"> </span></p>
	us-gaap	Revenues Revenues	865000	usd
	lgvn	Shortterm Investments ShorttermInvestments	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Short-term investments:</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Short-term investments at June 30, 2022 and December 31, 2021 consisted of marketable fixed income securities, primarily corporate bonds, as well as U.S. Government and agency obligations which are categorized as trading securities and are thus marked to market and stated at fair value in accordance with ASC 820 <i>Fair</i> <i>Value Measurement</i>. These investments are considered Level 1 and Level 2 investments within the ASC 820 fair value hierarchy. The fair value of Level 1 investments, including cash equivalents, money funds and U.S. government securities, are substantially based on quoted market prices. The fair value of corporate bonds is determined using standard market valuation methodologies, including discounted cash flows, matrix pricing and/or other similar techniques. The inputs to these valuation techniques include but are not limited to market interest rates, credit rating of the issuer or counterparty, industry sector of the issuer, coupon rate, call provisions, maturity, estimated duration and assumptions regarding liquidity and estimated future cash flows. In addition to bond characteristics, the valuation methodologies incorporate market data, such as actual trades completed, bids and actual dealer quotes, where such information is available. Accordingly, the estimated fair values are based on available market information and judgments about financial instruments categorized within Level 1 and Level 2 of the fair value hierarchy. Interest and dividends are recorded when earned. Realized gains and losses on investments are determined by specific identification and are recognized as incurred in the statement of operations. Changes in net unrealized gains and losses are reported in the statement of operations within other income and losses, in the current period and represent the change in the fair value of investment holdings during the reporting period. Changes in net unrealized gains and losses were not significant for the three and six months ended June 30, 2022 and 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"> </span></p>
CY2022Q2	lgvn	Accounts And Grants Receivable AccountsAndGrantsReceivable	136000	usd
CY2021Q4	lgvn	Accounts And Grants Receivable AccountsAndGrantsReceivable	55000	usd
	us-gaap	Revenues Revenues	836000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><b>Concentrations of credit risk: </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b> </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Financial instruments which potentially subject the Company to credit risk consist principally of cash and cash equivalents, short-term investments and accounts and grants receivable. Cash and cash equivalents are held in U.S. financial institutions. At times, the Company may maintain balances in excess of the federally insured amounts.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"> </span></p>
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3363000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3046000	usd
CY2022Q2	us-gaap	Revenues Revenues	466000	usd
CY2021Q2	us-gaap	Revenues Revenues	489000	usd
	us-gaap	Discontinued Operation Provision For Loss Gain On Disposal Net Of Tax DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax	0	usd
	us-gaap	Discontinued Operation Provision For Loss Gain On Disposal Net Of Tax DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax	6	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P10Y
CY2022Q2	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	42194000	usd
CY2021Q4	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	21823000	usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	700000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6198000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6108000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2835000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3062000	usd
CY2021Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	usd
CY2022Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	300000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	400000	usd
CY2022Q2	lgvn	Employment Agreements Description EmploymentAgreementsDescription	the Company appointed K. Chris Min, M.D., Ph.D. as its Chief Medical Officer. Dr. Min’s employment agreement provides annual base salary of $350,000, and he will be eligible to receive a performance bonus equal to 30% of his base salary, prorated for his first year of employment. Dr. Min received a $60,000 signing bonus, with 50% of this amount paid in RSUs and 50% in stock options. Dr. Min also received two equity incentive awards; 150,000 RSUs and a stock option award exercisable for 50,000 shares. Each award will vest 25% upon the first-year anniversary of his first day of employment with Longeveron, with 25% vesting thereafter on the second, third and fourth anniversaries of his employment. In each case, the vesting of the equity awards will be subject to Dr. Min’s continued service through the applicable vesting dates. RSUs shall be expensed on a quarterly basis at the rate of $0.1 million for the quarterly vesting amount of 9,375 RSUs, with a price per share of $12.85 (the closing price of the Company’s stock on April 4, 2022). Stock options shall be expensed based upon a Black-Scholes calculation, the price per share to be expensed was $11.34 and a total cost of $0.6 million would be expensed ratably over 48 months.
CY2022Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2931000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-573000	usd
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2358000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2807000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-473000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2334000	usd
CY2022Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	usd
CY2021Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	92000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	224000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	224000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	224000	usd
CY2022Q2	lgvn	Finite Lived Intangible Assets Amortization Expense Year Six FiniteLivedIntangibleAssetsAmortizationExpenseYearSix	224000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	482000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1470000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	40000	shares
CY2022Q2	lgvn	Rsu Per Share RSUPerShare	8.73
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	6.07
CY2022Q2	lgvn	Share Based Compensation Arrangement By Share Based Payment Award Option Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber	415473	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.21
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	5000	shares
CY2022Q2	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	8.73
CY2022Q2	lgvn	Calculation Price CalculationPrice	7.73
CY2021Q3	lgvn	Fair Market Value Per Share FairMarketValuePerShare	6.08
	us-gaap	Restricted Stock Shares Issued Net Of Shares For Tax Withholdings RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings	302046	shares
CY2021	us-gaap	Restricted Stock Shares Issued Net Of Shares For Tax Withholdings RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings	196751	shares
CY2022Q1	lgvn	Sharebased Compensation Arrangement Sharebased Payment Award Expiration Period SharebasedCompensationArrangementSharebasedPaymentAwardExpirationPeriod	P48M
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1400000	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	900000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3500000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1700000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	2900000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1800000	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3100000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	473000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	687000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	702000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	718000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	735000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	185000	usd
CY2022Q2	lgvn	Lessee Operating Lease Liability Payments LesseeOperatingLeaseLiabilityPayments	3500000	usd
	lgvn	Operating Lease Interest Expense OperatingLeaseInterestExpense	623000	usd
	lgvn	Present Value Of Lease Liability PresentValueOfLeaseLiability	2877000	usd
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	200000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	200000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	400000	usd
CY2021Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	400000	usd
CY2021Q2	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	10000000	usd
CY2022Q2	us-gaap	Sublease Income SubleaseIncome	0	usd
	us-gaap	Sublease Income SubleaseIncome	0	usd
CY2021Q2	us-gaap	Sublease Income SubleaseIncome	30000000	usd
	us-gaap	Sublease Income SubleaseIncome	60000000	usd
CY2021	lgvn	Underwriters Warrants UnderwritersWarrants	95760	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	17.5
CY2021Q4	lgvn	Warrants Expire Term WarrantsExpireTerm	P5Y
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	27854	shares
CY2022Q2	lgvn	Rsu Per Share RSUPerShare	6.1
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	196751	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	265189	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	131960	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	27934	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	302046	shares
	lgvn	Grant Shares GrantShares	0.05	pure
	lgvn	Dividend Yield dividendYield	0	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.95	pure
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	415473	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.21
	lgvn	Stock Option Issued And Outstanding StockOptionIssuedAndOutstanding	304449	shares
CY2022Q2	lgvn	Weighted Average Exercise Price WeightedAverageExercisePrice	5.96
CY2022Q2	lgvn	Total Stock Options Outstanding TotalStockOptionsOutstanding	415473	shares
CY2021Q4	lgvn	Total Stock Options Outstanding TotalStockOptionsOutstanding	304449	shares
CY2021Q4	lgvn	Share Based Compensation Arrangement By Share Based Payment Award Option Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber	304449	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.96
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	164160	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	10.33
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	374	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	5.73
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	100000	usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	22000	shares
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage	0.25	pure
CY2022Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	5.94
CY2022Q1	lgvn	Calculation Price CalculationPrice	5.23
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	100000	usd
CY2022Q1	lgvn	Sharebased Compensation Arrangement Sharebased Payment Award Expiration Period SharebasedCompensationArrangementSharebasedPaymentAwardExpirationPeriod	P48M
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	84825	shares
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage	0.25	pure
CY2022Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	10
CY2022Q1	lgvn	Calculation Price CalculationPrice	8.78
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2200000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	3500000	usd
	lgvn	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm	P3Y9M
CY2017Q4	lgvn	Aggregate Of Accrued Technology Service AggregateOfAccruedTechnologyService	200000	usd
CY2021Q4	us-gaap	Accounts Payable Other Current And Noncurrent AccountsPayableOtherCurrentAndNoncurrent	100000	usd
CY2022Q2	us-gaap	Accounts Payable Other Current And Noncurrent AccountsPayableOtherCurrentAndNoncurrent	100000	usd
CY2014Q4	lgvn	Licensing Agreement Description LicensingAgreementDescription	The Company is required to pay UM up to 3% of net sales on products or services developed from the technology. The agreement extends for up to 20 years from the last date a product or process is commercialized from the technology. Under the agreement, the Company is required to pay an annual fee to UM. On December 11, 2017, the original agreement with UM was amended. The amendment provided that for a $5,000 fee the dates of the milestone completions were amended and replaced as follows: (a) by December 31, 2021, to have completed Phase II clinical trials for the products; and (b) by September 1, 2025, to have completed Phase III clinical trials for products. In addition, one-year extensions may be granted on these milestone dates by making a payment of $5,000. Upon completion of the Phase II clinical trials, a milestone payment of $250,000 is due. Upon completion of the Phase III clinical trials, a milestone payment of $750,000 is due. As of June 30, 2022, the Company had accrued $46,667 based on the terms of the agreement. In addition, on November 14, 2014, as required by the license agreement the Company issued 20,000 series C membership units valued at $0.5 million to UM. The Company recorded this $500,000 as an intangible asset that is amortized over the life of the license agreement which was defined as 20 years.
CY2021Q1	us-gaap	Legal Fees LegalFees	100000	usd
CY2021Q1	lgvn	Defray Patent Costs DefrayPatentCosts	70000	usd
CY2021Q1	lgvn	Installments Paid InstallmentsPaid	7500	usd
CY2021Q1	lgvn	Isuuance Of Addritional Unrigistered Shares IsuuanceOfAddritionalUnrigisteredShares	110387	shares
	lgvn	Milestone Payments Description MilestonePaymentsDescription	The Company and UM agreed to the following modification of the milestone payments: (a) No payment will be due upon the completion of Phase 2 clinical trials for the product; (b) a one-time payment of $0.5 million, payable within six months of the completion of the first Phase 3 clinical trial of the products (based upon the final data unblinding); (c) a one-time payment of $0.5 million payable within six months of the receipt by the Company of approval for the first new drug application (“NDA”), biologics application (“BLA”), or other marketing or licensing application for the product; and (d) a one-time payment of $0.5 million payable within six months of the first sale following product approval.
CY2021Q3	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	1400000	usd
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	51000000	usd
	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	31000000	usd
CY2022Q2	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	19000000	usd
CY2021Q2	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	15000000	usd
	us-gaap	Stockholders Equity Other Shares StockholdersEquityOtherShares	718000	shares
	us-gaap	Stockholders Equity Other Shares StockholdersEquityOtherShares	988000	shares
	lgvn	Warrants Shares WarrantsShares	1271000	shares
	lgvn	Warrants Shares WarrantsShares	106000	shares
	lgvn	Antidilutive Securities Excluded From Computation Of Net Income Loss Amount Total AntidilutiveSecuritiesExcludedFromComputationOfNetIncomeLossAmountTotal	1989000	shares
	lgvn	Antidilutive Securities Excluded From Computation Of Net Income Loss Amount Total AntidilutiveSecuritiesExcludedFromComputationOfNetIncomeLossAmountTotal	1094000	shares
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2021Q2	lgvn	Nonoperating Lawsuit Expense NonoperatingLawsuitExpense		usd
CY2022Q2	lgvn	Forgiveness Of Paycheck Protection Program Loan ForgivenessOfPaycheckProtectionProgramLoan		usd
CY2021Q2	lgvn	Forgiveness Of Paycheck Protection Program Loan ForgivenessOfPaycheckProtectionProgramLoan		usd
CY2022Q2	us-gaap	Interest Expense InterestExpense		usd
	us-gaap	Interest Expense InterestExpense		usd
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures		usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
CY2022Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Other Nonrecurring Expense OtherNonrecurringExpense		usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1		usd
CY2021Q2	us-gaap	Revenue Remaining Performance Obligation Optional Exemption Remaining Duration RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration	P1Y
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001721484

Files In Submission

Name	View Source	Status
0001213900-22-047372-index-headers.html	Edgar Link	pending
0001213900-22-047372-index.html	Edgar Link	pending
0001213900-22-047372.txt	Edgar Link	pending
0001213900-22-047372-xbrl.zip	Edgar Link	pending
f10q0622ex31-1_longeveron.htm	Edgar Link	pending
f10q0622ex31-2_longeveron.htm	Edgar Link	pending
f10q0622ex32-1_longeveron.htm	Edgar Link	pending
f10q0622_longeveron.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
lgvn-20220630.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
lgvn-20220630_def.xml	Edgar Link	unprocessable
lgvn-20220630_lab.xml	Edgar Link	unprocessable
lgvn-20220630_pre.xml	Edgar Link	unprocessable
f10q0622_longeveron_htm.xml	Edgar Link	completed
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
lgvn-20220630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LGVN
Longeveron Inc. Stock $lgvn

2022 Q2 Form 10-Q Financial Statement

#000121390022047372 Filed on August 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LGVN Longeveron Inc. Stock $lgvn

2022 Q2 Form 10-Q Financial Statement

#000121390022047372 Filed on August 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LGVN
Longeveron Inc. Stock $lgvn